Osteopenia News and Research RSS Feed - Osteopenia News and Research

Osteopenia is a condition where bone mineral density is lower than normal. It is considered by many doctors to be a precursor to osteoporosis. However, not every person diagnosed with osteopenia will develop osteoporosis. More specifically, osteopenia is defined as a bone mineral density T-score between -1.0 and -2.5.
Celimmune to provide oral presentation on AMG 714 antibody at 16th International Coeliac Disease Symposium

Celimmune to provide oral presentation on AMG 714 antibody at 16th International Coeliac Disease Symposium

Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, announced today that Dr. Francisco Leon, CEO and Chief Medical Officer, will provide an oral presentation on an abstract related to the company's lead product candidate, AMG 714, at the 16th International Coeliac Disease Symposium, June 24, 2015, in Prague, Czech Republic. [More]
Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

Upsher-Smith Laboratories, Inc. announced that it has received U.S. Food and Drug Administration approval of a supplemental new drug application (sNDA) for Qudexy XR (topiramate) extended-release capsules for use as initial monotherapy in patients two years of age and older who are experiencing partial-onset seizures (POS) or primary generalized tonic-clonic seizures. [More]
Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith Laboratories, Inc. presented data from a 52-week, open-label extension study (PREVAIL OLE) showing that Qudexy XR (topiramate) extended-release capsules offered a long-term adjunctive treatment option with a favorable tolerability profile for a high proportion of patients with refractory partial-onset seizures (POS). [More]
New osteoporosis drug may also be useful for treating brittle bone disease

New osteoporosis drug may also be useful for treating brittle bone disease

New research at the University of Michigan offers evidence that a drug being developed to treat osteoporosis may also be useful for treating osteogenesis imperfecta or brittle bone disease, a rare but potentially debilitating bone disorder that that is present from birth. [More]
Celimmune licenses anti-IL-15 monoclonal antibody from Amgen

Celimmune licenses anti-IL-15 monoclonal antibody from Amgen

Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, announced today that it has licensed a Phase 2-stage, anti-IL-15 monoclonal antibody (AMG 714) from Amgen. [More]
Griffith study shows resistance training improves bone, muscle strength in post-menopausal women

Griffith study shows resistance training improves bone, muscle strength in post-menopausal women

Big improvements in strength with no injuries have been the hallmarks of success with a Griffith University study looking at the physical function of post-menopausal women. [More]
New syndrome osteosarcopenic obesity links deterioration of bone density and muscle mass with obesity

New syndrome osteosarcopenic obesity links deterioration of bone density and muscle mass with obesity

Florida State University researchers have identified a new syndrome called "osteosarcopenic obesity" that links the deterioration of bone density and muscle mass with obesity. [More]
NASA signs patent to develop novel biotechnology approaches that could have medical applications

NASA signs patent to develop novel biotechnology approaches that could have medical applications

NASA has signed two patent license agreements with GRoK Technologies LLC of Houston to help develop novel biotechnology approaches that could have multiple applications in space and on Earth. [More]
Research on calcium supplements and vitamin D, risk of fractures and more to be released at ASBMR

Research on calcium supplements and vitamin D, risk of fractures and more to be released at ASBMR

New research on calcium supplements and vitamin D, risk of fractures in older men, and the new culprit in bone fractures, weak muscles, and more will be released at the American Society for Bone and Mineral Research (ASBMR) 2013 Annual Meeting in Baltimore, the largest scientific meeting in the world on bone and mineral metabolism. [More]
New systematic review analyzes patterns of vitamin D status worldwide

New systematic review analyzes patterns of vitamin D status worldwide

A new systematic review published in the British Journal of Nutrition, is one of the first to focus on patterns of vitamin D status worldwide and in key population subgroups, using continuous values for 25(OH)D to improve comparisons. [More]
Low testosterone levels occur more often among men on long-acting opioids

Low testosterone levels occur more often among men on long-acting opioids

Low testosterone levels occur five times more often among men who take long-acting instead of short-acting opioids for chronic pain, according to a new Kaiser Permanente study published in The Clinical Journal of Pain. [More]
Complex process of bone disease evident in mastocytosis

Complex process of bone disease evident in mastocytosis

Patients with mastocytosis show elevated bone turnover that is associated with a higher mast cell load and advanced disease relative to individuals without the condition, suggest study findings. [More]
Osteoporosis medication Aclasta now available on Canadian public drug plans

Osteoporosis medication Aclasta now available on Canadian public drug plans

Osteoporosis Canada congratulates the Ontario government, the New Brunswick government, the Saskatchewan government and the British Columbia government for providing access to a new osteoporosis medication. Aclasta (zoledronic acid) is now available on public and private drug plans in Ontario, BC, SK, and NB meaning Canadians at high risk for fractures have access to increased treatment options. [More]
Study finds several osteoporosis risk factors among post-menopausal women on HRT

Study finds several osteoporosis risk factors among post-menopausal women on HRT

A preliminary study of 127 post-menopausal women on hormone replacement therapy in Portugal suggests that there are several risk factors associated with osteoporosis and bone fracture these include age, low bone mineral density, a sedentary lifestyle, coffee consumption and ovariectomy. Details are reported later this month in the International Journal of Medical Engineering and Informatics. [More]
EC grants European market authorization for Revestive to treat short bowel syndrome

EC grants European market authorization for Revestive to treat short bowel syndrome

Takeda Pharmaceutical Company Limited and NPS Pharmaceuticals, Inc., jointly announced today that the European Commission has granted European market authorization for the medicinal product teduglutide (trade name in Europe: Revestive) as a once-daily treatment for adult patients with short bowel syndrome. [More]
FDA committee to review NPS’ Gattex NDA in October

FDA committee to review NPS’ Gattex NDA in October

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing therapeutics for rare gastrointestinal and endocrine disorders, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that its New Drug Application (NDA) for Gattex (teduglutide) will be discussed at the Gastrointestinal Drugs Advisory Committee meeting scheduled for October 16, 2012. [More]
FDA extends PDUFA action date for NPS Gattex NDA

FDA extends PDUFA action date for NPS Gattex NDA

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing therapeutics for rare gastrointestinal and endocrine disorders, today announced that it has received a communication from the U.S. Food and Drug Administration extending the Prescription Drug User Fee Act action date for its New Drug Application for Gattex (teduglutide) by three months to December 30, 2012. [More]
Radiotherapy redundant in low-risk Hodgkin lymphoma treatment

Radiotherapy redundant in low-risk Hodgkin lymphoma treatment

Children with low-risk Hodgkin lymphoma who respond well to chemotherapy may not require additional radiotherapy, suggest study results. [More]
Platelet activation linked to osteoporosis

Platelet activation linked to osteoporosis

Elderly, postmenopausal women with osteoporosis have elevated platelet volumes, report researchers. [More]
European CHMP adopts positive opinion for teduglutide to treat short bowel syndrome

European CHMP adopts positive opinion for teduglutide to treat short bowel syndrome

Takeda Pharmaceutical Company Limited and NPS Pharmaceuticals, Inc., jointly announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product teduglutide (Revestive) as a once-daily treatment for adult patients with short bowel syndrome (SBS). [More]
Advertisement
Advertisement